BioFire Defense

Keeping you updated on critical diagnostic developments: As the response to the rare Bundibugyo Ebola outbreak expands, clinical diagnostics are taking center stage.

In a recent feature from Infection Control Today article, Matt Scullion of BioFire Defense explains why the rare Bundibugyo strain presents unique challenges, how modern diagnostic networks have improved since the 2014 Ebola crisis, and why identifying cases quickly may be the most effective intervention when vaccines and treatments are unavailable.

When managing high-consequence pathogens where licensed therapeutics or vaccines are limited, waiting for a delayed, single-target laboratory result is an operational risk. Frontline teams need highly sensitive, multiplexed molecular diagnostics at the point of care.

The BioFire®️ Global Fever Special Pathogens Panel addresses this diagnostic gap directly. Running on our standardized FilmArray footprint, it delivers rapid, syndromic multiplex PCR results in under an hour to help clinical teams identify, isolate, and manage high-consequence threats with confidence.

Read the full article on Infection Control Today: https://www.infectioncontroltoday.com/view/diagnostics-take-center-stage-ebola-response-rare-bundibugyo-outbreak-expands

Diagnostics Take Center Stage in Ebola Response as Rare Bundibugyo Outbreak Expands | Infection Control Today As the Ebola outbreak in the Democratic Republic of Congo and Uganda continues to grow, rapid diagnostic testing is emerging as one of the most important tools for outbreak containment. In this interview, Matt Scullion of BioFire Defense explains why the rare Bundibugyo strain presents unique challe...